Abstract
Cyclophosphamide 1.5 g m–2 followed by granulocyte colony-stimulating factor (G-CSF) is an effective peripheral blood stem cell (PBSC) mobilizing regimen, but has limited anti-lymphoma activity. We therefore assessed the mobilizing potential of ESHAP (etoposide, ara-C, methylprednisolone and cisplatin), a potent second-line lymphoma regimen followed by G-CSF. The results were compared in 78 patients with relapsed or resistant lymphomas with the use of cyclophosphamide 1.5 g m−2 followed by G-CSF in a matched pairs analysis, matching the ESHAP recipients (for predetermined prognostic factors) from a cohort of 178 lymphoma patients mobilized with cyclophosphamide and G-CSF. The total numbers of mononuclear cells collected at apheresis was similar with both regimens but ESHAP plus G-CSF resulted in a significantly higher percentage of CD34+ cells, absolute number of CD34+ cells and GM-CFC (all with P -values < 0.001). The number of patients requiring only one apheresis harvest to achieve a CD34+ cell yield of > 2.0 × 106kg–1 was greatly increased in the ESHAP recipients (56/78 vs 17/78, P< 0.001). The total number of progenitor cells collected was not significantly different with the two mobilization regimens because of this higher number of apheresis in the cyclophosphamide group. The proportion of patients who failed to achieve a minimum CD34+ cell target of 1 × 106kg–1 with the pooled harvests was less in the ESHAP arm (four patients vs nine patients) despite an increased number of aphereses in the cyclophosphamide recipients. ESHAP plus G-CSF is well tolerated and is an excellent mobilization regimen in patients with pre treated lymphoma. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, Gooley T, Demirer T, Schiffman K and Weaver C (1995) Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13: 2547–2555
Dreger P, Kloss M, Petersen B, Haferlach T, Loffler H, Loeffler M and Schmitz N (1995) Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 86: 3970–3978
Goldschmidt H, Hegenbart U, Haas R and Hunstein W (1996) Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 17: 691–697
Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M, Wannenmacher M and Hunstein W (1994) Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83: 3787–3794
Jones HM, Jones SA, Watts MJ, Khwaja A, Mills W, Fielding A, Goldstone AH and Linch DC (1994) Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma. J- Clin- Oncol 12: 1693–1702
Ketterer N, Salles G, Tremisi P, Espinous D, Raba M, Dumontet C, Moullet I, Niedhardt-Berard E-M, Boufafia F and Coiffier B (1997) Analysis of factors influencing 300 peripheral blood progenitor collections in 273 patients treated for lymphoproliferative diseases. Blood 90: 213a [abstract 939]
McQuaker IG, Haynes AP, Stainer C, Anderson S and Russell NH (1997) Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide [see comments]. Br J Haematol 98: 228–233
Morton J, Morton A, Bird R, Hutchins C and Durrant S (1997) Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate dose cyclophosphamide and G-CSF. Leuk Res 21: 21–27
Rowlings PA, Bayly JL, Rawling CM, Juttner CA and To LB (1992) A comparison of peripheral blood stem cell mobilisation after chemotherapy with cyclophosphamide as a single agent in doses of 4 g m–2or 7 g m–2in patients with advanced cancer. Aust N Z J Med 22: 660–664
Schwartzberg LS, Weaver CH, Birch R, Manner C, Tauer K, Beeker T, Morgan-Ihrig C, MacAneny B, Leff R, Smith R, Hainsworth J, Greco T, Schwerkoske J, Murphy MN and Buckner CD (1998) A randomized trial of two doses of cyclophosphamide with etoposide and G-CSF for mobilization of peripheral blood stem cells in 318 patients with stage II–III breast cancer. J Hematother 7: 141–150
Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E and Cabanillas F (1994) ESHAP–an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study [see comments]. J Clin Oncol 12: 1169–1176
Watts MJ and Linch DC (1997) Peripheral blood stem cell transplantation. Vox Sang 73: 135–142
Watts MJ, Sullivan AM, Jaimeson E, Chavda N, Fielding A, Goldstone AH and Linch DC (1995) A single apheresis algorithm for PBSCT. Br J Haematol 89: 22a (abstract 79)
Watts MJ, Leverett D, Sullivan AM, Peniket AJ, Perry AR, MacMillan A, Goldstone AH and Linch DC (1996) A comparison of ESHAP+G-CSF versus cyclophosphamide 1.5 g/m2+G-CSF for PBSC mobilisation in pretreated lymphoma patients. Blood 88: 396a
Watts MJ, Sullivan AM, Ings SJ, Leverett D, Peniket AJ, Perry AR, Williams CD, Devereux S, Goldstone AH and Linch DC (1997a) Evaluation of clinical scale CD34+ cell purification: experience of 71 immunoaffinity column procedures. Bone Marrow Transplant 20: 157–162
Watts MJ, Sullivan AM, Jamieson E, Pearce R, Fielding A, Devereux S, Goldstone AH and Linch DC (1997b) Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 15: 535–546
Watts MJ, Sullivan AM, Leverett D, Peniket AJ, Perry AR, Williams CD, Devereux S, Goldstone AH and Linch DC (1998) Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization. J Clin Oncol 16: 1554–1560
Weaver CH, Zhen B and Buckner CD (1998) Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34+ peripheral blood stem cells [letter]. Bone Marrow Transplant 21: 1169–1170
Zinzani PL, Barbieri E, Visani G, Gherlinzoni F, Perini F, Neri S, Bendandi M, Ammendolia I, Salvucci M and Babini L (1994) Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease. Haematologica 79: 508–512
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Watts, M., Ings, S., Leverett, D. et al. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m−2 and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer 82, 278–282 (2000). https://doi.org/10.1054/bjoc.1999.0915
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0915
Keywords
This article is cited by
-
Efficacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: a systematic review and network meta-analysis of randomized controlled trials
Stem Cell Research & Therapy (2022)
-
Stem cell transplant for mantle cell lymphoma in Taiwan
Scientific Reports (2022)
-
Correlative analysis of overall survival with clinical characteristics in 127 patients with mantle cell lymphoma: a multi-institutional cohort in Taiwan
International Journal of Hematology (2020)
-
Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study
Annals of Hematology (2016)
-
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
Bone Marrow Transplantation (2014)